BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33214972)

  • 1. Paclitaxel-Induced Palmar-Plantar Erythrodysesthesia.
    Wahab A; Khakwani M; Ehsan H; Bellam N
    Cureus; 2020 Nov; 12(11):e11507. PubMed ID: 33214972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group.
    Gogas H; Papadimitriou C; Kalofonos HP; Bafaloukos D; Fountzilas G; Tsavdaridis D; Anagnostopoulos A; Onyenadum A; Papakostas P; Economopoulos T; Christodoulou C; Kosmidis P; Markopoulos C
    Ann Oncol; 2002 Nov; 13(11):1737-42. PubMed ID: 12419745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal doxorubicin-related palmar-plantar erythrodysesthesia (hand-foot syndrome): a case report.
    Ni C; Fang J; Qian H; Xu Q; Shen F
    J Int Med Res; 2020 Dec; 48(12):300060520974854. PubMed ID: 33356712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palmar-plantar Erythrodysesthesia with Genital Involvement Secondary to Capecitabine Chemoradiotherapy: A Case Report.
    Hu HP; Corkum MT; Perera F
    Cureus; 2018 Dec; 10(12):e3704. PubMed ID: 30788193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).
    Templeton AJ; Ribi K; Surber C; Sun H; Hsu Schmitz SF; Beyeler M; Dietrich D; Borner M; Winkler A; Müller A; von Rohr L; Winterhalder RC; Rochlitz C; von Moos R; Zaman K; Thürlimann BJ; Ruhstaller T;
    Breast; 2014 Jun; 23(3):244-9. PubMed ID: 24656636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A variant of the chemotherapy-associated erythrodysesthesia syndrome related to high-dose cyclophosphamide.
    Matsuyama JR; Kwok KK
    DICP; 1989 Oct; 23(10):776, 778-9. PubMed ID: 2815854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An exploratory study to identify risk factors for the development of capecitabine-induced Palmar Plantar Erythrodysesthesia (PPE).
    Law A; Dyson S; Anthony D
    J Adv Nurs; 2015 Aug; 71(8):1825-32. PubMed ID: 25702709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
    Lambert-Falls R; Modugno S
    Clin Breast Cancer; 2007 Aug; 7(9):697-704. PubMed ID: 17919350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia.
    Lopez AM; Wallace L; Dorr RT; Koff M; Hersh EM; Alberts DS
    Cancer Chemother Pharmacol; 1999; 44(4):303-6. PubMed ID: 10447577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel-associated palmar-plantar erythrodysesthesia: a case report and review of the literature.
    Harris CS; Wang D; Carulli A
    J Oncol Pharm Pract; 2014 Feb; 20(1):73-80. PubMed ID: 23478198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
    Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
    Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment.
    Farr KP; Safwat A
    Case Rep Oncol; 2011 Apr; 4(1):229-35. PubMed ID: 21537373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palmar-plantar erythrodysesthesia secondary to docetaxel chemotherapy: a case report.
    Benghiat H; Al-Niaimi A
    J Med Case Rep; 2011 Feb; 5():80. PubMed ID: 21352522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
    Webster-Gandy JD; How C; Harrold K
    Eur J Oncol Nurs; 2007 Jul; 11(3):238-46. PubMed ID: 17350337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer drug induced palmar plantar erythrodysesthesia.
    Palaniappan M; Srinivasamurthy S; Dubashi B; Chandrasekaran A
    J Clin Diagn Res; 2014 Oct; 8(10):HC01-3. PubMed ID: 25478366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe palmar-plantar erythrodysesthesia and aplasia in an adult undergoing re-induction treatment with high-dose cytarabine for acute myelogenous leukemia: a possible drug interaction between posaconazole and cytarabine.
    Alzghari SK; Seago SE; Cable CT; Herrington JD
    J Oncol Pharm Pract; 2017 Sep; 23(6):476-480. PubMed ID: 27530244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
    Ajgal Z; Chapuis N; Emile G; Cessot A; Tigaud JM; Huillard O; Boudou-Rouquette P; Fontenay M; Goldwasser F; Alexandre J
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1033-9. PubMed ID: 26420236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).
    Lorusso D; Di Stefano A; Carone V; Fagotti A; Pisconti S; Scambia G
    Ann Oncol; 2007 Jul; 18(7):1159-64. PubMed ID: 17229768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
    Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scrotal and Penile Erythrodysesthesia Associated with Neoadjuvant Capecitabine Chemoradiation.
    Dricken J; Pettke E; Griffin JA; Li HY; Mehta V
    Cureus; 2020 Apr; 12(4):e7724. PubMed ID: 32432002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.